Abnormal Cannabidiol-d3

Abnormal cannabidiol-d3 contains three deuterium atoms at the terminal methyl position. It is intended for use as an internal standard for the quantification of abnormal cannabidiol by GC- or LC-mass spectrometry. Traditionally, the activity of cannabinoid (CB) agonists was thought to be transduced by a pair of G protein-coupled receptors, CB1 and CB2.{5240} Abnormal cannabidiol-d3 is a synthetic regioisomer of cannabidiol that fails to elicit either CB1 or CB2 responsiveness and is without psychotropic activity. Abnormal cannabidiol-d3 induces endothelium-dependent vasodilation via a CB1/CB2/nitric oxide-independent mechanism.{11092} At a dose of 20 µg/g in rats, abnormal cannabidiol-d3 showed hypotensive activity that could not be antagonized by cannabidiol or SR141716A. Abnormal cannabidiol-d3 is therefore believed to activate a third type of CB receptor, provisionally called the non-CB1/CB2 endocannabinoid receptor. Abnormal cannabidiol-d3 also acts via these receptors to regulate the migratory activity of murine BV-2 microglial cells, with an EC50 value of 600 nM.{12500}